RMD.NYSEResmed INC

Form 4: ResMed Inc. Executive Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Michael J. Rider, Global General Counsel of ResMed Inc., sold 69 shares of common stock at $242 per share under a pre-arranged 10b5-1 trading plan.

Summary

  • On November 1, 2024, Michael J. Rider, the Global General Counsel of ResMed Inc., sold 69 shares of ResMed Common Stock.
  • The sale was executed at a price of $242 per share.
  • The transaction was conducted under a Rule 10b5-1 plan adopted on May 11, 2024.
  • Following the transaction, Rider directly owns 10,443 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of an insider transaction under a pre-arranged trading plan. There's no indication of positive or negative implications for the company.

Industry Context

This is a routine disclosure of an insider transaction. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Key Dates

DateDescription
May 11, 2024Date the Rule 10b5-1 plan was adopted.
November 01, 2024Date of the transaction (sale of shares).
November 04, 2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.